Melanoma-specific survival. This is defined as the time between the date of a subject's randomization (or date of CLND for those randomized to the CLND arm) and the date of death due to melanoma. Subjects are followed until death or 10yrs.
Disease-free survival over 10 years of follow up
Recurrence during 10 years of follow up
18 Years to 75 Years (Adult, Senior)
MSLT-II P01CA029605 R01CA189163
March 1, 2006
February 6, 2018
Sharp Hospital San Diego, California, United States
John Wayne Cancer Institute Santa Monica, California, United States
Memorial Hospital - Colorado Springs Colorado Springs, Colorado, United States
(and 61 more...)
† Study has passed its completion date and status has not been verified in more than two years.